
News|Articles|July 15, 2007
Optimizing The Use Of Carbapenems In The Face Of Increasing Gram-Negative Resistance
As a result of the broad spectrum and enhanced potency of the carbapenems, this class of agents has long been held in reserve in an attempt to avoid the development of pathogen resistance to this important group of antimicrobials.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Looking ahead: What the MHE 2025 State of the Industry survey tells us about 2026
2
What IRA drug prices will mean for PBMs, health plans and patients
3
The trend toward post-infusion outpatient care of patients treated with CAR-T | ASH 2025
4
Biosimilars in 2025: A year of firsts
5





















































